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Background & Aims:	 Insulin	resistance	is	a	risk	marker	for	non-	alcoholic	fatty	liver	
disease,	and	a	risk	factor	for	liver	disease	progression.	We	assessed	temporal	trajec-
tories	 of	 insulin	 resistance	 and	 β-	cell	 response	 to	 serum	 glucose	 concentration	
throughout	adulthood	and	their	association	with	diabetes	risk	in	non-	alcoholic	fatty	
liver disease.
Methods:	 Three	 thousand	 and	 sixty	 participants	 from	 Coronary	 Artery	 Risk	
Development	 in	 Young	 Adults,	 a	 prospective	 bi-	racial	 cohort	 of	 adults	 age	 18-	
30	years	at	baseline	(1985-	1986;	Y0)	who	completed	up	to	5	exams	over	25	years	and	





Results:	 Three	 distinct	 trajectories	 were	 identified,	 separately,	 for	 homeostatic	
model	assessment	 insulin	resistance	(low-	stable	[47%];	moderate-	increasing	[42%];	
and	 high-	increasing	 [12%])	 and	 homeostatic	 model	 assessment-	β	 (low-	decreasing	
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1  | INTRODUC TION













improving	 IR	alone	does	not	appear	sufficient	 to	 resolve	NAFLD.6,7 
One	speculative	explanation	for	these	findings	might	be	that	despite	
improvement	in	 insulin	sensitivity,	pancreatic	β-	cell	function	contin-
ues	 to	deteriorate	and	 thus	 targeting	 insulin	 sensitivity	alone	has	a	
null	 effect.	 Recent	 data	 demonstrate	 that	 biopsy-	proven	NAFLD	 is	
associated	with	an	exaggerated	pancreatic	β-	cell	response.8	However,	
clinical	 imaging-	based	NAFLD	studies	have	 failed	 to	demonstrate	a	
relationship	 between	 NAFLD	 and	 pancreatic	 β-	cell	 dysfunction.9,10 
There	 are	 a	 lack	 of	 population-	level	 studies	 examining	 changes	 in	
pancreatic	β-	cell	response	to	blood	glucose	concentration	throughout	
adulthood	in	relation	to	changes	in	IR	on	NAFLD	and	T2DM.
Surrogate	 indicators	 for	 IR,	 as	 well	 as	 pancreatic	 β-	cell	 re-
sponse	to	glucose	concentration,	can	be	extrapolated	from	fasting	
blood	 glucose	 and	 insulin	 levels	 that	 are	 commonly	 included	 in	
population-	based	 studies.	 The	 homeostatic	 model	 assessments	
(HOMA)	are	simple	methods	for	estimating	β-	cell	response	to	glu-
cose	 concentration	 and	 how	well	 insulin	 is	 utilized	 by	 its	 target	
cell	populations.11	Specifically,	HOMA-	IR	 is	a	measure	 for	whole	




during	 young	 adulthood	 in	 relation	 to	 prevalent	 NAFLD	 in	mid-
dle	adulthood	and	subsequent	risk	of	T2DM	among	persons	with	
NAFLD.
[16%];	 moderate-	decreasing	 [63%];	 and	 high-	decreasing	 [21%]).	 Y25	 non-	alcoholic	
fatty	 liver	disease	prevalence	was	24.5%.	Among	non-	alcoholic	 fatty	 liver	disease,	






















middle	 age	 is	 associated	 with	 greatest	 risk	 of	 NAFLD	
and	subsequent	diabetes.
•	 Thus,	 how	 insulin	 resistance	 develops	 in	 NAFLD	 pro-
vides	important	information	about	risk	of	diabetes	inde-
pendent	of	degree	of	insulin	resistance	in	middle	age.







low-	up	 exams	 at	 2,	 5,	 7,	 10,	 15,	 20	 and	 25	years	 after	 baseline	
included	 extensive	 collection	 of	 detailed	 clinical	 data,	 includ-





centre	 (University	 of	 Alabama	 at	 Birmingham,	 Birmingham,	 AL;	




Y20,	 and	 Y25.	 Measures	 at	 examinations	 when	 the	 participant	
was	pregnant	were	excluded	(n	=	192).	Measures	at	examinations	
when	the	participant	reported	taking	exogenous	insulin	were	ex-
cluded	 for	 calculation	 of	 HOMA-	β	 (n	=	29).11,13	 Of	 3060	 partic-
ipants	 with	 fasting	measures	 at	 Y0	 and	 at	 3	 or	 more	 follow-	up	





dard	 drinks/week	 in	 men	 (n	=	225),7	 human	 immunodeficiency	
virus	 (n	=	14),	 and	medications	 (eg,	 valproic	 acid,	 methotrexate,	
tamoxifen	 and/or	 amiodarone;	 n	=	22).	 The	 remaining	2104	par-








after	 a	 12-	hour	 fast	 in	 the	 seated	 position,	 separated	 and	 plasma	
frozen	to	−70°C	prior	to	analysis	 in	a	central	 laboratory.12 Glucose 










The	 presence	 of	 T2DM	 was	 assessed	 at	 each	 examination	
based	on	a	combination	of	medication	use	 for	T2DM	(every	exam-
ination),	 FPG	≥126	mg/dL	 (Y0,	Y7,	Y10,	Y15,	Y20	and	Y25),	 2-	hour	
glucose	≥200	mg/dL	 (Y10,	Y20	and	Y25)	by	OGTT,	or	haemoglobin	




The	CT	protocol	 included	 the	heart	 and	 abdomen	using	 a	 non-	
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<1)16	 and	moderate-	severe	NAFLD	 as	 a	 LA	 ≤40	HU	 (equivalent	 to	
≥30%	liver	fat)	after	exclusion	of	other	liver	fat	causes.15
2.3 | Statistical analysis
Group-	based	 trajectory	modelling	was	used	 to	 identify	 and	 cat-
egorize	participants	based	on	patterns	of	 longitudinal	 change	 in	
HOMA-	IR	or	HOMA-	β	during	the	25	years	of	follow-	up	(N	=	3060	
for	HOMA-	IR,	N	=	3031	for	HOMA-	β).17	HOMA-	IR	and	HOMA-	β 
were	 logarithmically	 transformed	 to	 approximate	 normality.	
Models	 were	 fit	 using	 SAS	 Proc	 traj.18	 Group-	based	 trajectory	
analysis	 is	designed	 to	 identify	 clusters	of	 individuals	with	 simi-
lar	patterns	of	 change	over	 time.	The	optimal	number	of	 trajec-
tory	 classes	 was	 determined	 using	 the	 Bayesian	 information	
criterion	such	that	no	group	included	less	than	5%	of	participants.	
Participants	were	assigned	to	the	trajectory	group	for	which	they	









tors	 (pack-	years	of	 smoking,	physical	activity	 [exercise	units	per	
year],	 alcohol	 use	 [drinks/week],	 systolic	 blood	 pressure	 [SBP],	
total/high	density	lipoprotein	cholesterol	[HDL-	C]	ratio	and	num-
ber	 of	 visits	with	 blood	 pressure	 or	 lipid-	lowering	medications),	
percent	 change	 in	 BMI	 relative	 to	 baseline,	 and	 HOMA-	IR	 or	
HOMA-	β	at	Y0	or	Y25.	Cumulative	SBP,	alcoholic	beverages,	phys-
ical	 activity	 and	 total-	HDL-	C	 ratio	 were	 calculated	 by	 summing	




included	 in	 the	 final	model	 (Model	3)	 as	a	dichotomous	variable	






the	 1593	NAFLD-	eligible	 participants	with	 CT	 liver	 attenuation	
>51	HU	(eg,	non-	NAFLD)	in	CARDIA	(Figure	S1).
Finally,	 three	 mutually	 exclusive	 clusters	 were	 defined	 based	
on	 hypothesized	 β-	cell	 response	 and	 IR	 dynamics	 using	 observed	
HOMA-	IR	 and	 HOMA-	β	 trajectory	 group	 membership	 pair	 (eg,	
increasing	 IR	 promotes	 β-	cell	 demise	 and	 inhibits	 β-	cell	 compen-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.1 | HOMA- IR and HOMA- β trajectories





(n	=	1285)	 had	moderate	 increase	 in	 IR	 (moderate-	increasing)	 and	
12%	(n	=	346)	had	high	increase	in	IR	(high-	increasing).	For	HOMA-	β,	
all	 trajectory	 groups	 demonstrated	 a	 decrease	 in	 HOMA-	β	 after	
age	 45	 (Figure	1B).	 However,	 the	 majority	 of	 participants	 main-
tained	 fairly	 HOMA-	β	 throughout	most	 of	 young	 adulthood:	 21%	
(n	=	626)	 had	 high-	decreasing	 HOMA-	β	 and	 63%	 (n	=	1917)	 had	
moderate-	decreasing	HOMA-	β.	Only	16%	(n	=	488)	of	participants	
demonstrated	a	notable	early	 and	 sustained	decrease	 in	HOMA-	β 
throughout	young	adulthood	(eg,	low-	decreasing).
Participant	 characteristics	 at	 Y0	 according	 to	 HOMA	 tra-
jectory	 group	 are	 presented	 in	 Table	1.	 Individuals	 with	 high-	
decreasing	 HOMA-	β	 were	 older	 and	 predominantly	 women	 and	
black.	 Individuals	with	 high-	decreasing	HOMA-	β	 were	more	 likely	
to	be	overweight	or	obese	compared	to	individuals	with	moderate-	
decreasing	and	low-	decreasing	HOMA-	β.	Similarly,	individuals	with	
high-	increasing	 HOMA-	IR	 were	 predominantly	 women,	 black	 and	
had	higher	 baseline	BMI	 compared	 to	 the	 low-	stable	 IR	 group.	At	
Y25,	 participants	 with	 moderate-	decreasing	 and	 high-	decreasing	
HOMA-	β	 were	 more	 likely	 to	 display	 features	 of	 the	 metabolic	
syndrome	 compared	 to	 participants	 in	 the	 low-	decreasing	 group	
(Table	2).	 Similar	 trends	were	 seen	 in	 participants	with	moderate-	
increasing	or	high-	increasing	IR	throughout	adulthood	compared	to	
participants	with	low-	stable	IR	(Table	2).
3.2 | HOMA trajectories and NAFLD
Non-	alcoholic	fatty	liver	disease	prevalence	in	CARDIA	was	24.5%	
and	 was	 higher	 with	 increasing	 HOMA-	IR	 group.	 Any	 NAFLD	
(eg,	 LA	<	51	HU)	was	 present	 in	 7.4%,	 32.5%,	 and	 63.6%	 in	 the	
low-	stable,	 moderate-	increasing	 and	 high-	increasing	 HOMA-	IR	





tion	by	 race	or	 gender	 in	 all	models	 and	 thus	pooled	 results	 are	
shown.
Table	3	 demonstrates	 the	 association	 between	 HOMA-	IR	
or	 HOMA-	β	 trajectory	 group	 and	 continuous	 LA	 or	 NAFLD.	 For	
HOMA-	IR,	those	in	trajectory	groups	with	patterns	of	 increasingly	
severe	 IR	 (referent:	 low-	stable)	 had	 progressively	 greater	 odds	 of	
having	 any	NAFLD	 after	 adjustment	 for	 demographic	 characteris-
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cumulative	NAFLD	risk	factors,	including	Y0	HOMA-	β.	Associations	
were	attenuated	more	 substantially,	 but	 remained	 statistically	 sig-
nificant	when	adjusted	for	Y25	HOMA-	β.	The	association	between	
HOMA-	β	 trajectory	 and	 continuous	 LA	 and	 moderate-	severe	
NAFLD	 (n	 events	=	224)	 was	 similar	 in	 direction	 and	 magnitude	
(Table	3).	 In	 sensitivity	 analyses	 excluding	 those	 participants	 who	
were	 taking	T2DM	medications	 at	 any	 time	point,	 all	 associations	
were	unchanged	(data	not	shown).
3.3 | HOMA trajectories and T2DM among NAFLD 
participants
Among	 participants	 with	 any	 NAFLD	 (n	=	511),	 both	 prevalent	
and	 incident	 T2DM	 at	 Y25	 was	 higher	 with	 increasing	 HOMA-	IR	
(P	<	.0001,	Figure	3A).	In	contrast,	participants	with	low-	decreasing	
HOMA-	β	trajectory	had	the	highest	prevalence	of	T2DM	(P	<	.0001,	
Figure	3B).	 In	multivariable	 analysis,	 low-	decreasing	HOMA-	β	 (ref-
erent:	high-	decreasing)	trajectory	was	associated	with	higher	odds	
of	 prevalent	 (OR	=	11.8	 [4.3,	 32.4])	 and	 incident	 (OR	=	9.1	 [3.4,	
24.3])	 T2DM	 independent	 of	 cumulative	 T2DM	 risk	 factors	 and	
Y25	 HOMA-	IR	 (Table	4).	 In	 contrast,	 high-	increasing	 HOMA-	IR	
(referent:	low-	stable)	trajectory	was	associated	with	greater	preva-
lent	 (OR	=	4.6	 [1.1,	18.9])	and	 incident	 (OR	=	7.2	 [1.8,	29.2])	T2DM	
(Table	4).	 Findings	 were	 similar	 in	 direction	 though	 somewhat	
stronger	 in	 magnitude	 in	 both	 unadjusted	 and	 adjusted	 analyses	
among	non-	NAFLD	CARDIA	participants	who	were	excluded	from	
the	primary	analyses	(n	=	1593,	Table	S1).








(61.4%)	 and	women	 (63.8%),	 and	participants	with	 low	HOMA	 IR-	
low	HOMA	β	cluster	were	predominantly	white	(67.2%)	and	women	












referent.	 In	 terms	of	T2DM	risk,	NAFLD	participants	 in	 the	high	
HOMA	 IR-	high	HOMA	β	 cluster	 had	 significantly	higher	odds	of	
both	prevalent	and	incident	T2DM	in	the	base	model,	but	associ-
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collectively,	 persons	 with	 high	 β-	cell	 response,	 in	 relation	 to	 high	
IR	had	 the	highest	odds	of	 prevalent	NAFLD	and	T2DM	 in	midlife	
independent	 of	 cumulative	metabolic	 confounders.	 These	 findings	
highlight	 early	 identification	 of	 increasing	 IR	 and	 pancreatic	 β-	cell	
response	 to	glucose,	as	potential	 targets	 for	primary	prevention	of	
NAFLD	and	T2DM	in	NAFLD.
Multiple	studies	have	demonstrated	hyperinsulinaemia,	and	thus	
elevated	HOMA-	IR,	 in	NAFLD.19	 IR	 is	 inadequate	 response	by	 tis-
sues	to	the	physiological	effects	of	insulin.	IR	is	thus	tissue-	specific.	
HOMA-	IR	typically	reflects	hepatic	 IR.20	However,	the	 liver	 is	also	
the	 primary	 site	 of	 insulin	 clearance	 in	 humans.21	 Several	 studies	
have	shown	that	HOMA-	IR	elevation	in	NAFLD	is	primarily	related	
to	 impaired	 hepatic	 insulin	 clearance	 rather	 than	 impaired	 insulin	
suppression	of	hepatic	glucose	production.1,22	Thus,	HOMA-	IR	may	
be	a	poor	overall	marker	of	hepatic	IR	in	NAFLD	and	the	relationship	








We	also	demonstrate	 that	 high	pancreatic	β-	cell	 response	 to	
glucose	throughout	adulthood	is	a	marker	of	NAFLD	independent	
of	metabolic	 risk	 factors.	 Previous	 studies	 likewise	 demonstrate	
that	liver	fat	is	associated	with	absolute	increases	in	insulin	secre-
tion	 from	 the	β-	cell,	 in	order	 to	compensate	 for	 IR	and	maintain	
euglycemia.24	 It	 has	 also	 been	 demonstrated	 that	 NAFLD	 is	 as-
sociated	with	pancreatic	β-	cell	dysfunction	in	non-	diabetic	obese	
subjects.8,9	NAFLD	individuals	have	an	exaggerated	β-	cell	 insulin	
secretory	 response	 to	 an	oral	 glucose	 load	 independent	of	BMI,	
age	and	sex;	and	a	decline	in	β-	cell	 index,	which	reflects	pancre-
atic	β-	cell	function,	in	the	setting	of	underlying	IR.8,23	Our	current	
findings	 add	 to	 the	 epidemiological	 evidence	 that	 increasing	 IR	







Prevalent Y25 T2DM 
N events/total N = 136/511a
OR (95% CI)
Incident Y25 T2DM 
N events/total N = 144/508a
OR (95% CI)
Nd Model 1 Model 2 Model 3 Nd Model 1 Model 2 Model 3
HOMA-	IR	trajectoryb
Low-	stable 3/72 Reference 3/72 Reference
Moderate-	
increasing
42/290 3.1	(0.91,	10.3) 1.7	(0.48,	6.2) 1.2	(0.32,	4.4) 47/289 3.6*	(1.1,	12.0) 2.2	(0.62,	8.1) 1.7	(0.46,	6.2)
High-	
increasing




27/48 9.4‡	(4.1,	21.5) 14.1‡	(3.9,	50.9) 11.8‡	(4.3,	32.4) 27/48 7.2‡	(3.2,	16.2) 10.3‡	(2.7,	39.3) 9.1‡	(3.4,	24.3)
Moderate-	
decreasing
58/282 1.1	(0.70,	1.8) 1.6	(0.79,	3.2) 1.5	(0.92,	2.9) 63/282 1.0	(0.64,	1.6) 1.3	(0.62,	2.6) 1.7	(0.94,	2.9)
High-	
decreasing
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fat	content.	Thus,	HOMA-	β	may	be	a	poor	overall	marker	of	pan-
creatic	β-	cell	function	in	NAFLD.	Prospective	studies	that	assess	
rate	of	change	 in	hepatic	 insulin	clearance	over	 time	are	needed	
to	 fully	understand	the	role	of	 IR	and	pancreatic	β-	cell	 response	
during	NAFLD	development.
Progression	to	diabetes	is	a	complex	interplay	among	IR,	 in-
sulin	 sensitivity,	 and	 pancreatic	 β-	cell	 function.	 A	 decrease	 in	
sensitivity	 to	 insulin	demands	 compensation	 through	a	propor-
tionate	 adjustment	 in	 insulin	 secretion	 by	 pancreatic	 β-	cells	 to	
maintain	 glucose	 homeostasis.25	 On	 a	 population-	level,	 T2DM	






IR and low β-	cell	response.	 In	contrast,	 low	IR	despite	 low	pan-
creatic	 β-	cell	 response	 was	 associated	 with	 a	 36%	 decreased	
odds	of	T2DM	suggesting	that	IR	is	the	primary	driver	of	T2DM	
in	 NAFLD.	 Once	 established,	 T2DM	may	 promote	 progression	

















obesity.	 Since	 undiagnosed	NAFLD	may	 have	 been	 present	 early	
in	follow	up,	we	also	cannot	rule	out	the	possibility	of	reverse	cau-
sality	(eg,	NAFLD	causing	an	increase	in	IR,	rather	than	vice	versa).	
CARDIA	only	 included	whites	 and	 blacks	 and	 did	 not	 specifically	
ask	about	ethnicity.	Thus,	we	cannot	generalize	our	findings	to	the	





use	 repeated	OGTT	 or	 frequent	 sampling	 of	 intravenous	 glucose	
tolerance	 test	 or	 c-	peptide	 levels	 to	measure	 IR	 or	 pancreatic	 β-	
















































BMI,	body	mass	 index;	CI,	confidence	 interval;	HDL,	high	density	 lipo-


































in	early	adulthood	or	 in	midlife.	 In	 the	age	of	 the	electronic	medi-
cal	 record,	 repeated	measures	 of	 insulin	 sensitivity	 and	 secretion	
throughout	adulthood	can	be	readily	graphed	allowing	clinicians	to	
recognize	at-	risk	patterns	 (eg,	 rapidly	 rising	 IR)	early	 in	adulthood.	
Early	 identification	of	young	adults	with	high	HOMA-	IR	trajectory	








baseline	 and	 concurrent	 IR	 and	 β-	cell	 response—may	 provide	 ad-
ditional	 information	about	the	cumulative	burden	of	 IR	and	risk	of	
prevalent	 NAFLD	 and	 T2DM	 in	 midlife.	 These	 associations	 were	
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